Allergan's UK Generics Business Up For Sale Under EC Merger Condition
This article was originally published in Scrip
Executive Summary
The European Commission has approved the proposed $40.5bn acquisition of the generics business of Allergan (the company formerly known as Actavis) by Teva, subject to a number of significant conditions, including the divestment of the majority of Allergan Generics' business in the UK and Ireland.
You may also be interested in...
Intas' MD On Acquiring Best-Performing Assets And Brexit
India's largest privately held pharmaceutical company, Intas, says that it understands Europe well and that the best-performing assets acquired from Teva there are a "perfect fit" for its business. Intas vice chair and managing director Binish Chudgar spoke to Scrip on the buyout and why Brexit isn't a major concern - at least for now.
Intas Builds Europe Scale With £603m Teva Deal
Intas Pharmaceuticals of India has acquired certain Teva assets in Europe – a transaction that is expected to give the unlisted Indian group significantly expanded scale in the region.
M&A Trends: The Growing Indian Appetite
A recent round table on pharma industry trends has highlighted the hunger of cash-rich Indian firms for acquiring companies with niche portfolios in regulated markets including the US. Innovator companies shedding their generic units also present significant opportunities for Indian firms. Both trends are expected to build amid apparent Indian interest in the Teva-Allergan divestiture in Europe.